Roche Confirms Outlook for 2025 After Strong Revenue With key Drugs

A stronger Swiss franc, however, dampened the relative growth in this currency, according to Roche. Roche (i) reported impressive results in the first half of 2025, with strong corporate growth of 7% at constant exchange rates amounting to CHF 30.9 billion. Notably, core earnings per share rose by 12%, and net profit according to IFRS increased by 23% to CHF 7.8 billion. This is mainly attributable to strong operational performance and lower impairments on intangible assets. Pharmaceutical division as a growth driver The pharmaceutical division...